Saturday, September 23, 2023
Saturday, September 23, 2023

Anderson Heart Partners with Azura Vascular Care & National Cardiovascular Partners

Anderson Heart, PC (Anderson Heart or AH), an independent cardiology and vascular surgery practice headquartered in Anderson, South Carolina, has partnered with Azura Vascular Care and National Cardiovascular Partners, LP, together wholly owned by Fresenius Medical Care North America, to form a newly created joint venture that completes an equity recapitalization and focuses on a growth strategy of physician recruitment and providing high-quality medical care to patients throughout South Carolina, at the advice of The Capital Corporation

The Capital Corporation, a boutique investment bank headquartered in Greenville, South Carolina, offering particular expertise in the health services sector, served as the exclusive investment banking advisor to Anderson Heart on the transaction.

Anderson Heart was formed in 2006 as an independent cardiology medical practice by founder and current Chief Executive Officer, Dr. Brent McLaurin. Since formation, AH added three additional physicians including one cardiologist and two vascular surgeons. In 2017, AH designed and constructed a wholly-owned, freestanding, independent clinic from which its four physicians conduct their practice of medicine.

Anderson Heart provides the highest-quality medical services to its patients from its owned clinic and local hospitals as necessary. Further, AH does so at lower overall cost to patients and third-party reimbursors such as the Centers for Medicare and Medicaid Services (“CMS”) and numerous independent health insurance companies. CMS is part of the Department of Health and Human Services and oversees the U.S. government’s Medicare and Medicaid programs.

Azura Vascular Care, a division of Fresenius Medical Care North America, is a national leader in the field of vascular specialty services. Operating and managing outpatient vascular care and ambulatory surgery centers throughout the United States and Puerto Rico, Azura’s physicians and trained medical specialists perform minimally invasive procedures focusing on excellence in clinical outcomes and delivering a great customer experience to patients with various vascular conditions that can be treated safely in an outpatient setting.

National Cardiovascular Partners, a division of Fresenius Medical Care North America, partners with physicians to create, sustain and grow independent ambulatory surgery centers and catheterization labs. Its focus is on hybrid surgery center and outpatient cardiac catheterization lab services, in partnership with physician entrepreneurs. NCP currently operates surgery centers and physician practices throughout the U.S. For more information, please visit the NCP website at

The Capital Corporation: Now in its 30th year of operation, The Capital Corporation continues to provide its publicly traded and privately held middle-market client companies quality advisory services to help them achieve their financial objectives. With hundreds of closed transactions, The Capital Corporation is one of the most successful middle-market investment banking firms in the country, differentiated by its team’s experience, commitment, and unwavering focus on achieving client objectives. As a member of IMAP, The Capital Corporation is part of the world’s largest alliance of independent M&A advisory firms offering local expertise and global connections through more than 60 offices in over 40 countries.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy